Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OptiBiotix HealthSTU:OB3 -4.55% ROC (Joel Greenblatt) % is -1,635.44% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 1,323 Biotechnology companies, OptiBiotix Health ranks worse than 72.86% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. OptiBiotix Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -1,635.44%.
The historical rank and industry rank for OptiBiotix Health's ROC (Joel Greenblatt) % or its related term are showing as below:
STU:OB3'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -94866.67 Med: -553.35 Max: 17842.11
Current: -1560.8
During the past 13 years, OptiBiotix Health's highest ROC (Joel Greenblatt) % was 17842.11%. The lowest was -94866.67%. And the median was -553.35%.
STU:OB3's ROC (Joel Greenblatt) % is ranked worse than 72.86% of 1323
companies
in the Biotechnology industry
Industry Median: -297.52
vs STU:OB3: -1560.80
OptiBiotix Health's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
OptiBiotix Health (STU:OB3) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
OptiBiotix Health ROC (Joel Greenblatt) % Related Terms
OptiBiotix Health ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for OptiBiotix Health's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:OB3 vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, OptiBiotix Health's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptiBiotix Health ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OptiBiotix Health's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where OptiBiotix Health's ROC (Joel Greenblatt) % falls into.
OptiBiotix Health ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -1,635.44% mean?
OptiBiotix Health (STU:OB3) has a ROC (Joel Greenblatt) % of -1,635.44% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on OptiBiotix Health and its competitors. According to the industry distribution chart, OptiBiotix Health ranks #964 out of 1323 companies in the Biotechnology industry, placing it in the top 72.9%.
Is OptiBiotix Health's ROC (Joel Greenblatt) % too high?
OptiBiotix Health's current ROC (Joel Greenblatt) % is -1,635.44%. Based on the distribution chart, OptiBiotix Health ranks #964 out of 1323 companies in the Biotechnology industry, which is below the industry midpoint.
How does OptiBiotix Health's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OptiBiotix Health ranks #964 out of 1323 companies for ROC (Joel Greenblatt) %. This places OptiBiotix Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on OptiBiotix Health and its competitors. OptiBiotix Health's current ROC (Joel Greenblatt) % is -1,635.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
OptiBiotix Health (STU:OB3) has a current ROC (Joel Greenblatt) % of -1,635.44%. The stock's GF Value™ is €0.34, compared to a current price of €0.06 — trading 81.5% below its estimated fair value. The current ROC (Joel Greenblatt) % is -1,635.44%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For OptiBiotix Health (STU:OB3), the current ROC (Joel Greenblatt) % is -1,635.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OB3 has been successfully added to your 
